The IASLC, Guardant Health, the Global Lung Cancer Coalition and AstraZeneca announced the Lung Ambition Alliance, a new partnership to eliminate lung cancer as a cause of death.
The U.S. Food and Drug Administration approved Pfizer Inc.’s biosimilar to Roche Holding AG’s blockbuster cancer treatment Avastin.
With the books closed on another ASCO meeting, it’s clear to see that checkpoint inhibitors keep showing a promise.
There was a flurry of activity during the first few days of the American Society of Clinical Oncology, with multiple presentations made showing the benefits of various oncology treatments.
An experimental Amgen Inc. drug that targets a specific genetic mutation significantly reduced tumor size in half of evaluated patients with advanced lung cancer in a small, early-stage trial, sending the U.S. biotechnology company’s share up nearly 6 percent.
Nearly a quarter of patients who received Merck & Co.’s immunotherapy Keytruda as an initial treatment for advanced lung cancer were still alive after five years, according to data presented at a major medical meeting.
AbbVie is slashing 178 jobs from the company’s Stemcentrx subsidiary in South San Francisco.
AstraZeneca will pay up to $6.9 billion to work with Daiichi Sankyo on a hotly tipped experimental treatment for breast cancer, in a direct challenge to the world’s largest cancer drug maker Roche.
Swiss drugmaker Roche Holding AG’s U.S. unit Genentech Inc. won approval for the immunotherapy Tecentriq for a tough-to-treat type of lung cancer.